Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epirubicin · 2 trials · 1 indication
For the purpose of this study, a pathologic complete response (pCR) was defined as no evidence of residual invasive tumor in the breast (pT0) and axillary lymph nodes (pN0), gross or microscopic, in the sample removed at the time of surgical resection. Residual ductal or lobular carcinoma in situ was not considered in pCR assessments. Percentage of participants who experienced pCR is reported.
For the purpose of this study, a Pathologic complete response (pCR) was defined as no evidence of residual invasive tumor in the breast (pT0). Residual ductal or lobular carcinoma in situ was not considered in pCR assessments. Percentage of participants who experienced pCR is reported.
| Arm | Type | Description |
|---|---|---|
| Intervention | EXPERIMENTAL | Patients were treated with 6 doses of neoadjuvant gemcitabine 2000 mg/m2, epirubicin 50 mg/m2, and albumin-bound paclitaxel 175 mg/m2 intravenously administered at 14-day intervals. Following neoadjuvant chemotherapy, patients underwent either mastectomy or breast conservation surgery; pathologic response to treatment was assessed. Postoperatively, patients received 4 doses of gemcitabine 2000 mg/m2 with albumin-bound paclitaxel 220 mg/m2 at 14-day intervals. Pegfilgrastim 6 mg was administered subcutaneously on day 2 following each dose of chemotherapy. |
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles |
| Epirubicin | DRUG | Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles |
| Albumin-bound Paclitaxel | DRUG | ABI-007 175 mg/m2 D1 q 14 days x 6 cycles |
| Docetaxel | DRUG | Docetaxel |
Inclusion Criteria: To be included in this study, you must meet the following criteria: * Locally advanced/inflammatory adenocarcinoma of the breast * 18 years of age or older * Normal heart function * Able to perform activities of daily living with minimal assistance * No prior chemotherapy for b...
Top 20 of 92 competitors
Epirubicin is a small molecule oncology drug being studied for the treatment of breast cancer, specifically in locally advanced or inflammatory breast cancer. It is currently in Phase 2 clinical development and is being investigated as part of combination chemotherapy regimens.
Epirubicin is being developed by Eli Lilly and Company, which trades under the ticker symbol LLY on the stock exchange. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with breast cancer.
Epirubicin is currently in Phase 2 clinical development for breast cancer. It is an investigational drug and has not yet been approved by regulatory authorities. Two Phase 2 trials have been completed, with a total of 233 patients enrolled across both studies.
Epirubicin has been studied in two completed Phase 2 clinical trials. NCT00193050 evaluated weekly gemcitabine, epirubicin, and docetaxel in locally advanced or inflammatory breast cancer with 110 female participants. NCT00193206 assessed neo-adjuvant gemcitabine, epirubicin, and ABI-007 (GEA) in the same patient population with 123 female participants in the United States.
Epirubicin is a small molecule drug used in oncology. It works by interfering with the replication of cancer cells, ultimately leading to cell death. This mechanism makes it effective in treating breast cancer when used in combination with other chemotherapeutic agents.